MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22
September 19, 2025 16:18 ET | Source: MBX Biosciences, Inc. CARMEL, Ind.,…
Faraday Future Announces Strategic $41 Million Investment in Qualigen Therapeutics, Inc. (NASDAQ: QLGN) f for Crypto Business Through PIPE Transaction
LOS ANGELES and CARLSBAD, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Faraday Future…
Revive Therapeutics Announces Closing of Second Tranche of Private Placement
TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or…
Algernon Announces Preferred Share Class Approved at Annual and Special Meeting
VANCOUVER, British Columbia, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the…
Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $9 Million Public Offering
September 18, 2025 21:26 ET | Source: Reviva Pharmaceuticals CUPERTINO, Calif., Sept.…
Japan Ground Self-Defense Force Adopts MEDIROM MOTHER Labs REMONY for Advanced Health Monitoring and Heatstroke Safety
TOKYO, Sept. 18, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ:…
NovaBay Pharmaceuticals Issues a Reminder of Important Information Regarding the Pending Special Dividend and Upcoming 2025 Annual Meeting
September 18, 2025 16:30 ET | Source: NovaBay Pharmaceuticals Inc. EMERYVILLE, Calif.,…
89bio, Inc. Announces Agreement to be Acquired by Roche
September 18, 2025 01:02 ET | Source: 89bio, Inc. – 89bio stockholders…
Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH
89bio’s pegozafermin allows for a potentially best-in-disease treatment for moderate to severe…
